Biblio

33557 resultats trouvés
A
Daien V, Garcher CPCreuzot, Delyfer M-N, Bron AM, Gillies MC, Lacombe S, Papinaud L, Cholley D, Domerg C, Cougnard-Gregoire A et al..  2017.  A Pharmacoepidemiological study of intravitreal drug consumption in the first 12 months of treatment. The EPIdemiology and SAFEty collaboration. INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE. 58
Olivier G, Clavert A, Lacotte-Thierry L, Gardembas M, Escoffre-Barbe M, Brion A, Cumin I, Legouffe E, Solal-Celigny P, Chabin M et al..  2014.  A phase 1 dose escalation study of idarubicin combined with methotrexate, vindesine, and prednisolone for untreated elderly patients with primary central nervous system lymphoma: The GOELAMS LCP 99 trial. AMERICAN JOURNAL OF HEMATOLOGY. 89:1024-1029.
Herbst RS, Bendell JC, Isambert N, Calvo E, Santana-Davila R, Cassier P, Perez-Gracia JLuis, Yang J, Rege J, Ferry D et al..  2016.  A phase 1 study of ramucirumab (R) plus pembrolizumab (P) in patients (pts) with advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, non-small cell lung cancer (NSCLC), or urothelial carcinoma (UC): Phase 1a results. JOURNAL OF CLINICAL ONCOLOGY. 34
Curigliano G., Loibl S., Mueller V., Pivot X., Wardley A., Cameron D..  2016.  A phase 2 randomized, double-blinded, controlled study of ONT-380 vs. placebo in combination with capecitabine (C) and trastuzumab (T) in patients with pretreated HER2+unresectable locally advanced or metastatic breast carcinoma (MBC). ANNALS OF ONCOLOGY. 27
Gressin R, Daguindau N, Tempescul A, Moreau A, Carras S, Tchernonog E, Schmitt A, Houot R, Dartigeas C, Pignon JMichel et al..  2019.  A phase 2 study of rituximab, bendamustine, bortezomib and dexamethasone for first-line treatment of older patients with mantle cell lymphoma. HAEMATOLOGICA. 104:138-146.
Kalakonda N, Cavallo F, Follows G, Goy A, Vermaat JSP, Casasnovas O, Lavee O, Maerevoet M, Zijlstra J, Bakhshi S et al..  2019.  A Phase 2b Study of Selinexor in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL). CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 19:S248-S249.
Fizazi K, Maldonado X, Foulon S, Roubaud G, McDermott RS, Flechon A, Tombal BF, Supiot S, Berthold DR, Ronchin P et al..  2021.  A phase 3 trial with a 2x2 factorial design of abiraterone acetate plus prednisone and/or local radiotherapy in men with de novo metastatic castration-sensitive prostate cancer (mCSPC): First results of PEACE-1.. JOURNAL OF CLINICAL ONCOLOGY. 39
Truc G., Bernier V., Mirjolet C., Dalban C., Mazoyer F., Bonnetain F., Blanchard N., Lagneau E., Maingon P., Noel G..  2016.  A phase I dose escalation study using simultaneous integrated-boost IMRT with temozolomide in patients with unifocal glioblastoma. CANCER RADIOTHERAPIE. 20:193-198.
Dieras V, Bachelot T, Campone M, Isambert N, Joly F, Le Tourneau C, Cassier P, Bompas E, Fumoleau P, Noal S et al..  2016.  A Phase I, Dose-Escalation Trial of Pazopanib in Combination with Cisplatin in Patients with Advanced Solid Tumors: A UNICANCER Study. ONCOLOGY AND THERAPY. 4:211-223.
Isambert N, Elez E, Zanetta S, Matos I, Nazabadioko S, Xue W, Carriere P, Tabernero J.  2018.  A phase I, open-label dose-escalation trial of weekly (qw) BI 836880, a vascular endothelial growth factor (VEGF)/angiopoietin-2 (Ang-2)-blocking Nanobody, in patients (pts) with advanced/metastatic solid tumors.. JOURNAL OF CLINICAL ONCOLOGY. 36
Fumoleau P, Koch KM, Brain E, Lokiec F, Rezai K, Awada A, Hayward L, Werutsky G, Bogaerts J, Marreaud S et al..  2014.  A phase I pharmacokinetics study of lapatinib and tamoxifen in metastatic breast cancer (EORTC 10053 Lapatam study). BREAST. 23:663-669.
Nelken B, Cave H, Leverger G, Galambrun C, Plat G, Schmitt C, Thomas C, Verite C, Brethon B, Gandemer V et al..  2016.  A Phase I Study of Clofarabine With Multiagent Chemotherapy in Childhood High Risk Relapse of Acute Lymphoblastic Leukemia (VANDEVOL Study of the French SFCE Acute Leukemia Committee). PEDIATRIC BLOOD & CANCER. 63:270-275.
Morschhauser F, Salles GAndre, Casasnovas R-O, Feugier P, Bouabdallah K, Cartron G, Bouabdallah R, Nicolas-Virelizier E, Maerevoet M, Snauwaert S et al..  2018.  A Phase II Lysa Study of Obinutuzumab Combined with Lenalidomide for Advanced Untretated Follicular B-Cell Lymphoma in Need of Systemic Therapy. BLOOD. 132
Morschhauser F, Cartron G, Salles GA, Bijou F, Fruchart C, Bouabdallah K, Feugier P, Le Gouill S, Tilly H, Molucon-Chabrot C et al..  2016.  A Phase II LYSA Study of Obinutuzumab Combined with Lenalidomide for Relapsed or Refractory Aggressive B-Cell Lymphoma. BLOOD. 128
Pautier P., Penel N., Ray-Coquard I., Italiano A., Bompas E., Delcambre C., Bay J.-O, Bertucci F., Delaye J., Chevreau C. et al..  2020.  A phase II of gemcitabine combined with pazopanib followed by pazopanib maintenance, as second-line treatment in patients with advanced leiomyosarcomas: A unicancer French Sarcoma Group study (LMS03 study). EUROPEAN JOURNAL OF CANCER. 125:31-37.
Sun XShan, Sire C, Tao Y, Martin L, Alfonsi M, Prevost JBriac, Rives M, Lafond C, Tourani J-M, Biau J et al..  2018.  A phase II randomized trial of pembrolizumab versus cetuximab, concomitant with radiotherapy (RT) in locally advanced (LA) squamous cell carcinoma of the head and neck (SCCHN): First results of the GORTEC 2015-01 ``PembroRad'' trial.. JOURNAL OF CLINICAL ONCOLOGY. 36
Coiffier B, Thieblemont C, de Guibert S, Dupuis J, Ribrag V, Bouabdallah R, Morschhauser F, Navarro R, Le Gouill S, Haioun C et al..  2016.  A phase II, single-arm, multicentre study of coltuximab ravtansine (SAR3419) and rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma. BRITISH JOURNAL OF HAEMATOLOGY. 173:722-730.
Selle F., Sevin E., Ray-Coquard I., Mari V., Berton-Rigaud D., Favier L., Fabbro M., Lesoin A., Lortholary A., Pujade-Lauraine E..  2014.  A phase II study of lenalidomide in platinum-sensitive recurrent ovarian carcinoma. ANNALS OF ONCOLOGY. 25:2191-2196.
Galot R., Le Tourneau C., Saada-Bouzid E., Daste A., Even C., Debruyne P.R, Henry S., Zanetta S., Rutten A., Licitra L.F et al..  2019.  A phase II study of monalizumab in patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN): Results of the I1 cohort of the EORTC-HNCG-1559 trial (UPSTREAM). ANNALS OF ONCOLOGY. 30
Van Den Neste E, Andre M, Gastinne T, Stamatoullas A, Haioun C, Belhabri A, Reman O, Casasnovas O, Ghesquieres H, Verhoef G et al..  2018.  A phase II study of the oral JAK1/JAK2 inhibitor ruxolitinib in advanced relapsed/refractory Hodgkin lymphoma. HAEMATOLOGICA. 103:840-848.
Bonnefoi H., Grellety T., Tredan O., Saghatchian M., Dalenc F., Mailliez A., L'Haridon T., Cottu P., Abadie-Lacourtoisie S., You B. et al..  2016.  A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1). ANNALS OF ONCOLOGY. 27:812-818.
Amela E, Bompas E, Le Cesne A, Tresch E, Italiano A, Piperno-Neumann S, Collard O, Vansteene D, Domont J, Saada E et al..  2015.  A phase II trial of sorafenib (SO) in advanced chordoma patients (pt). JOURNAL OF CLINICAL ONCOLOGY. 33
Bui-Nguyen B., Butrynski J.E, Penel N., Blay J.Y, Isambert N., Milhem M., Kerst J.M, Reyners A.KL, Litiere S., Marreaud S. et al..  2015.  A phase IIb multicentre study comparing the efficacy of trabectedin to doxorubicin in patients with advanced or metastatic untreated soft tissue sarcoma: The TRUSTS trial. EUROPEAN JOURNAL OF CANCER. 51:1312-1320.
Daver NGuastad, Montesinos P, DeAngelo DJ, Wang ES, Todisco E, Tarella C, Martinelli G, Erba HPaul, Deconinck E, Sweet KL et al..  2020.  A phase I/II study of IMGN632, a novel CD123-targeting antibody-drug conjugate, in patients with relapsed/refractory acute myeloid leukemia, blastic plasmacytoid dendritic cell neoplasm, and other CD123-positive hematologic malignancies.. JOURNAL OF CLINICAL ONCOLOGY. 38
Daver NGuastad, Montesinos P, DeAngelo DJ, Wang ES, Todisco E, Tarella C, Martinelli G, Erba HPaul, Deconinck E, Sweet KL et al..  2020.  A phase I/II study of IMGN632, a novel CD123-targeting antibody-drug conjugate, in patients with relapsed/refractory acute myeloid leukemia, blastic plasmacytoid dendritic cell neoplasm, and other CD123-positive hematologic malignancies.. JOURNAL OF CLINICAL ONCOLOGY. 38

Pages